CTLA4 and neoplasm: Therapy resistance, e.g. against cytostatic drugs, but also immunotherapies such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, is still a major clinical challenge in the treatment of PDAC patients, and has been related to tumor heterogeneity implying the presence of CSCs (12–16).